Biomedical Engineering Reference
In-Depth Information
available clinically are too insensitive to detect the LSC population, highlight-
ing the importance of understanding LSC biology so that novel stem cell
markers and treatments can be identified and more robust measurements of
the rare LSC population and its size can be undertaken.
References
Abrahamsson, A., Geron, I., Gotlib, J., Dao, K.-H., Giles, F., Newton, I., Kavalerchik, E.,
Durocher, J., Creusot, R., Karimi, M., Jones, C., Zehnder, J., Keating, A., Negrin, R.,
Weissman, I. L. and Jamieson, C. H. M. 2007. Missplicing of glycogen synthase kinase 3b:
a potential mechanism of blast crisis chronic myeloid leukemia stem cell generation. Blood
110:238a-9a.
Argiropoulos, B. and Humphries, R. K. 2007. Hox genes in hematopoiesis and leukemogen-
esis. Oncogene 26:6766-76.
Artavanis-Tsakonas, S., Rand, M. D. and Lake, R. J. 1999. Notch signaling: cell fate control
and signal integration in development. Science 284:770-6.
Aster, J. C., Pear, W. S. and Blacklow, S. C. 2008. Notch signaling in leukemia. Annu Rev
Pathol 3:587-613.
Attar, E. C., Deangelo, D. J., Supko, J. G., D'Amato, F., Zahrieh, D., Sirulnik, A., Wadleigh,
M., Ballen, K. K., McAfee, S., Miller, K. B., Levine, J., Galinsky, I., Trehu, E. G.,
Schenkein, D., Neuberg, D., Stone, R. M. and Amrein, P. C. 2008. Phase I and pharma-
cokinetic study of bortezomib in combination with idarubicin and cytarabine in patients
with acute myelogenous leukemia. Clin Cancer Res 14:1446-54.
Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A.,
Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. 1983.
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromo-
some in chronic myelocytic leukaemia. Nature 306:277-80.
Blair, A. and Sutherland, H. J. 2000. Primitive acute myeloid leukemia cells with long-term
proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp
Hematol 28:660-71.
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M. and Sutherland, H. J. 1997. Lack of
expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative
ability in vitro and in vivo. Blood 89:3104-12.
Blair, A., Hogge, D. E. and Sutherland, H. J. 1998. Most acute myeloid leukemia progenitor
cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/
CD71(-)/HLA-DR. Blood 92:4325-35.
Bonnet, D. and Dick, J. E. 1997. Human acute myeloid leukemia is organized as a hierarchy
that originates from a primitive hematopoietic cell. Nat Med 3:730-7.
Borrow, J., Shearman, A. M., Stanton, V. P., Jr., Becher, R., Collins, T., Williams, A. J.,
Dube, I., Katz, F., Kwong, Y. L., Morris, C., Ohyashiki, K., Toyama, K., Rowley, J. and
Housman, D. E. 1996. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia
fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet
12:159-67.
Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K., Browett, P., Schwarer, A.,
Bradstock, K., Arthur, C., Durrant, S., Ma, D., Joske, D., Lynch, K. and Hughes, T. 2004.
BCR-ABL levels continue to decrease up to 42 months after commencement of standard
dose imatinib in patients with newly diagnosed chronic phase CML who achieve a
molecular response. Blood 104:82a.
Brummendorf, T. H., Holyoake, T. L., Rufer, N., Barnett, M. J., Schulzer, M., Eaves, C. J.,
Eaves, A. C. and Lansdorp, P. M. 2000. Prognostic implications of differences in telomere
